Innovating and Scaling Entrepreneurial Ventures in Peru

Last registered on April 22, 2025

Pre-Trial

Trial Information

General Information

Title
Innovating and Scaling Entrepreneurial Ventures in Peru
RCT ID
AEARCTR-0015569
Initial registration date
April 20, 2025

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
April 22, 2025, 12:18 PM EDT

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Locations

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Primary Investigator

Affiliation
Stanford University

Other Primary Investigator(s)

PI Affiliation
Texas A&M
PI Affiliation
World Bank
PI Affiliation
Texas A&M

Additional Trial Information

Status
On going
Start date
2020-01-01
End date
2027-12-31
Secondary IDs
Prior work
This trial does not extend or rely on any prior RCTs.
Abstract
This study investigates the effectiveness of a business accelerator focused on growth that combines managerial and financial capital to enhance the commercialization in early-stage entrepreneurial ventures in Peru. While innovation-driven ventures have significant potential to contribute to economic development, they often face substantial barriers in scaling their operations, particularly in developing countries. The study aims to address these challenges by implementing a targeted intervention that includes the hiring of Chief Revenue Officers (CROs), intensive go-to-market training, and structured mentoring and pitch events.
To rigorously evaluate the impact of these interventions, the study employs a randomized controlled trial (RCT) design involving 220 early-stage ventures. Participants were randomly assigned to either a treatment group, which will receive the full set of interventions, or a control group, which will not receive any support during the study period. The effectiveness of the interventions will be assessed through detailed baseline and follow-up, with a focus on measuring changes in performance indicators such as sales and profits. The study also aims to identify which types of ventures benefit most from the intervention, providing valuable insights for policymakers and researchers interested in fostering entrepreneurial growth in similar contexts.
External Link(s)

Registration Citation

Citation
Anderson, Stephen et al. 2025. "Innovating and Scaling Entrepreneurial Ventures in Peru." AEA RCT Registry. April 22. https://doi.org/10.1257/rct.15569-1.0
Experimental Details

Interventions

Intervention(s)
Intervention Start Date
2020-12-01
Intervention End Date
2022-06-01

Primary Outcomes

Primary Outcomes (end points)
Main effects will be measured on firm sales, firm profits and an overall performance index.
Primary Outcomes (explanation)

Secondary Outcomes

Secondary Outcomes (end points)
In addition, we will also try to identify the mechanisms or processes through which the intervention impacts firm sales and profits. We will focus on product-related outcomes (i.e., quantity, quality, and related outcomes).
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
Our sample consists of 220 entrepreneurs. We used the sampsi command in Stata for our a priori power calculations. The baseline data was collected and verified for this set of firms (N = 220), and the participants were randomly assigned into two experimental groups:

1. Group 1 (Treatment): 110 entrepreneurs will be offered the managerial capital support.

2. Group 2 (Control): 110 entrepreneurs will form a comparison group who do not receive any intervention during the study period.
Experimental Design Details
Not available
Randomization Method
Randomization done on a computer, using statistical programming software (Stata).
Randomization Unit
The randomization unit is an individual firm/entrepreneur (N = 220 units).
Was the treatment clustered?
No

Experiment Characteristics

Sample size: planned number of clusters
None.
Sample size: planned number of observations
220 firms/entrepreneurs
Sample size (or number of clusters) by treatment arms
1. N = 110 in Treatment
2. N = 110 in Control
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
IRB

Institutional Review Boards (IRBs)

IRB Name
IPA
IRB Approval Date
2022-02-09
IRB Approval Number
N/A